Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]
It was approved for use in the European Union in August 2013.[1]
Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]
^ abcde"Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Archived from the original on 12 November 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
